Mcdaniel Terry & Co. Sells 1,633 Shares of Stryker Corporation $SYK

Mcdaniel Terry & Co. lessened its holdings in Stryker Corporation (NYSE:SYK) by 2.5% in the second quarter, Holdings Channel reports. The institutional investor owned 64,907 shares of the medical technology company’s stock after selling 1,633 shares during the period. Stryker accounts for approximately 2.1% of Mcdaniel Terry & Co.’s holdings, making the stock its 21st largest position. Mcdaniel Terry & Co.’s holdings in Stryker were worth $25,679,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mid American Wealth Advisory Group Inc. bought a new stake in shares of Stryker in the 2nd quarter valued at about $26,000. Sachetta LLC boosted its holdings in Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after acquiring an additional 27 shares during the last quarter. Goodman Advisory Group LLC acquired a new stake in Stryker during the 1st quarter valued at approximately $32,000. Ridgewood Investments LLC raised its holdings in Stryker by 48.4% during the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after purchasing an additional 30 shares during the last quarter. Finally, Ransom Advisory Ltd bought a new position in Stryker during the 1st quarter worth approximately $37,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Down 0.3%

SYK stock opened at $381.86 on Friday. The stock’s 50 day moving average is $379.84 and its 200-day moving average is $379.73. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The firm has a market capitalization of $145.99 billion, a PE ratio of 50.58, a P/E/G ratio of 2.76 and a beta of 0.94. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $5.92 billion. During the same period last year, the business earned $2.81 EPS. The business’s revenue was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Sell-side analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker’s dividend payout ratio (DPR) is 44.50%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on SYK shares. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Needham & Company LLC lifted their price objective on Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Rothschild & Co Redburn started coverage on Stryker in a research note on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price objective on the stock. Evercore ISI decreased their target price on Stryker from $418.00 to $410.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. Finally, UBS Group set a $408.00 price target on Stryker in a research note on Monday, October 13th. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $432.24.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Viju Menon sold 500 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.